Breaking News Instant updates and real-time market news.

FB

Facebook

$182.64

-1.13 (-0.61%)

06:12
04/25/19
04/25
06:12
04/25/19
06:12

Facebook upgraded to Buy from Neutral at UBS

UBS analyst Eric Sheridan upgraded Facebook to Buy from Neutral and raised his price target for the shares to $240 from $170. The stock in premarket trading is up 9%, or $15.69, to $198.27. While 2019 remains a year of transition, Facebook management has now produced multiple quarters of better than expected revenue and earnings, Sheridan tells investors in a research note following last night's Q1 results. Instagram is now one of the Internet's large scaled digital ad platforms that can sustain growth and operating leverage for years to come, contends the analyst. Further, he believes that while concerns will persist about core Facebook maturation, regulatory headwinds and safeguarding the platform for a privacy first approach, the "market now better understands many of those risks." Facebook's operating momentum is greater than business transition fears, Sheridan concludes.

  • 28

    Apr

  • 30

    May

  • 03

    Jun

FB Facebook
$182.64

-1.13 (-0.61%)

04/23/19
FBCO
04/23/19
NO CHANGE
Target $211
FBCO
Outperform
Signs of potential value creation from Facebook new products, says Credit Suisse
Credit Suisse analyst Stephen Ju continues to anticipate the real clearing data point for Facebook shares will arrive on the Q3 report, in which he expects the OpEx/CapEx outlook to signal a return to growth for free cash flow. In the meantime, ahead of Q1 results, his checks continue to suggest minimal deceleration for U.S. budgets coupled with modest headwinds in Europe. Ju also believes there are "greater signs" of potential value creation from new products. The analyst reiterates an Outperform rating on the shares, while raising his price target on the stock to $211 from $210, as he believes Facebook will be able to drive long-term revenue growth without a material lift in ad loads with, the Street models continue to underestimate the long-term monetization potential of other billion-user properties like Messenger and WhatsApp, and free cash flow growth recovery for 2020.
04/24/19
OPCO
04/24/19
NO CHANGE
Target $44
OPCO
Outperform
Twitter price target raised to $44 from $33 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Twitter (TWTR) to $44 from $33 as platform improvements are driving mDAUs and monetization remains strong. The analyst notes that the company's machine learning initiatives have been proactive, flagging 38% of abusive Tweets before being seen. In general, the company has navigated public policy issues better than peers Alphabet (GOOG) and Facebook (FB), he contends. Helfstein reiterates an Outperform rating on Twitter's shares.
04/25/19
BARD
04/25/19
NO CHANGE
Target $215
BARD
Outperform
Facebook price target raised to $215 from $195 at Baird
Baird analyst Colin Sebastian raised his price target for Facebook to $215 from $195 following last night's Q1 results and keeps an Outperform rating on the shares. The stock in premarket trading is up 8%, or $15.42, to $198.00. Facebook reported better than expected revenue, as pricing headwinds from Instagram Feed/Stories mix was offset by stronger user engagement, Sebastian tells investors in a research note. Further, management reduced 2019 expense growth guidance to reflect better investment visibility and lower new headcount, adds the analyst. He believes Facebook will continue to benefit disproportionately from its scale and resource advantages relative to most competitors. Sebastian points out, however, that Facebook management expects revenue growth to decelerate sequentially through the end of 2019 due to the impacts from re-targeting headwinds and internal policies.
04/25/19
MZHO
04/25/19
NO CHANGE
Target $230
MZHO
Buy
Facebook price target raised to $230 from $210 at Mizuho
Mizuho analyst James Lee raised his price target for Facebook to $230 from $210 saying the company last night reported "strong" Q1 results with a "positive" outlook for 2019. Revenue growth guidance is expected to be decelerating for the rest of 2019, "consistent with consensus but conservative in our view," Lee tells investors in a post-earnings research note. The only "negative spot" was a $3B accrued expense for FTC inquiry, which would take some time to resolve, adds the analyst. He keeps a Buy rating on Facebook.

TODAY'S FREE FLY STORIES

TYPE

Monotype Imaging

$17.90

1.41 (8.55%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Recommendations
Monotype Imaging analyst commentary  »

Private equity buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMLC

VanEck Vectors J.P. Morgan EM Local Currency Bond ETF

$34.54

0.27 (0.79%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Options
Upside call buyer in thinly traded Emerging Markets Sovereign Debt ETF »

Upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

11:29
06/20/19
06/20
11:29
06/20/19
11:29
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:28
06/20/19
06/20
11:28
06/20/19
11:28
Syndicate
Akero Therapeutics indicated to open at $16.76, IPO priced at $16.00 »

Akero Therapeutics (AKRO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

11:25
06/20/19
06/20
11:25
06/20/19
11:25
General news
Oil Action: WTI crude advanced as much as 6% »

Oil Action: WTI crude…

QGEN

Qiagen

$41.02

0.34 (0.84%)

11:25
06/20/19
06/20
11:25
06/20/19
11:25
Conference/Events
Qiagen to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 06

    Aug

AIR

AAR Corp.

$33.83

0.125 (0.37%)

11:23
06/20/19
06/20
11:23
06/20/19
11:23
Hot Stocks
AAR, Tawazun Economic Council and GAL sign joint repair management deal »

AAR announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GO

Grocery Outlet

$0.00

(0.00%)

11:22
06/20/19
06/20
11:22
06/20/19
11:22
Syndicate
Breaking Syndicate news story on Grocery Outlet »

Grocery Outlet indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

11:20
06/20/19
06/20
11:20
06/20/19
11:20
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNLN

Greenlane

$12.23

1.25 (11.38%)

11:19
06/20/19
06/20
11:19
06/20/19
11:19
Recommendations
Greenlane analyst commentary  »

Greenlane fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$47.60

-5.25 (-9.93%)

11:18
06/20/19
06/20
11:18
06/20/19
11:18
Downgrade
Carnival rating change  »

Carnival downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CTST

CannTrust

$5.31

-0.05 (-0.93%)

, CURR

CURE Pharmaceutical

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
On The Fly
Rising High: CannTrust launches U.S. operations with California JV »

In this week's "Rising…

CTST

CannTrust

$5.31

-0.05 (-0.93%)

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CGC

Canopy Growth

$43.05

0.275 (0.64%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

TLRY

Tilray

$47.00

1.55 (3.41%)

IIPR

Innovative Industrial Properties

$135.35

10.335 (8.27%)

ORTFD

Biome Grow

$0.00

(0.00%)

APHA

Aphria

$6.75

0.01 (0.15%)

ACB

Aurora Cannabis

$7.46

-0.025 (-0.33%)

MMNFF

MedMen

$0.00

(0.00%)

ORHOF

Origin House

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

CRON

Cronos Group

$16.50

0.655 (4.14%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.32

0.09 (7.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

NDVAF

INDIVA

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

MRRCF

Wayland Group

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

SNNVF

Sunniva

$0.00

(0.00%)

HMDEF

DionyMed Brands

$0.00

(0.00%)

SRUTF

Sproutly

$0.00

(0.00%)

GRWG

Grow Generation

$0.00

(0.00%)

HRVSF

Harvest Health & Recreation

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
06/20/19
06/20
11:16
06/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$24.52

0.23 (0.95%)

11:15
06/20/19
06/20
11:15
06/20/19
11:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Treasury announced a $113 B in coupon sales for next week »

Treasury announced a $113…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BGNE

BeiGene

$124.98

4.98 (4.15%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Hot Stocks
BeiGene announces Phase 1b results of zanubrutinib with Gazyva »

BeiGene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Syndicate
Breaking Syndicate news story on Personalis »

Personalis indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AMRN

Amarin

$19.82

0.4 (2.06%)

11:08
06/20/19
06/20
11:08
06/20/19
11:08
On The Fly
Jefferies sees Amarin stock poised for even more gains »

Seeing the stock's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

STLD

Steel Dynamics

$29.25

-0.45 (-1.52%)

11:05
06/20/19
06/20
11:05
06/20/19
11:05
Options
Steel Dynamics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Hot Stocks
Breaking Hot Stocks news story on Misonix »

Misonix up 39c to $24.17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$5.28

-1.02 (-16.19%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Recommendations
Melinta Therapeutics analyst commentary  »

Gabelli fears Melinta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:03
06/20/19
06/20
11:03
06/20/19
11:03
Hot Stocks
SEC tells Misonix investigation concluded, no enforcement action recommended »

Misonix announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.